Developing and scaling COVID-19 vaccines

13 May 2020

Mark McClellan (Duke-Margolis, United States), Anthony S Fauci (National Institute of Allergy and Infectious Diseases, United States), Adrian Hill (Jenner Institute, United Kingdom), Tal Zaks (Moderna Therapeutics Inc, United States), John Reed (Sanofi, France), Peter Marks (Center for Biologics Evaluation and Research, United States), Luciana Borio (In-Q-Tel, United States), Paul Stoffels (Johnson & Johnson, United States), Richard Hatchett (Coalition for Epidemic Preparedness Innovations, Norway), Victor Dzau (National Academy of Medicine, United States) and Scott Gottlieb (American Enterprise Institute, United States)